[1]李竹英,陈 璐,王丽洁.麻黄-白果药对“异病同治”支气管哮喘和慢性阻塞性肺疾病药理作用研究[J].陕西中医,2021,(8):1128-1132.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.035]
　LI Zhuying,CHEN Lu,WANG Lijie.Pharmacological mechanism of Ephedra and Ginkgo couplet medicine in treating asthma and COPD based on treating different diseases with the same treatment[J].,2021,(8):1128-1132.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.035]
点击复制

麻黄-白果药对“异病同治”支气管哮喘和慢性阻塞性肺疾病药理作用研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2021年8期
页码:
1128-1132
栏目:
方药纵横
出版日期:
2021-08-05

文章信息/Info

Title:
Pharmacological mechanism of Ephedra and Ginkgo couplet medicine in treating asthma and COPD based on treating different diseases with the same treatment
作者:
李竹英1; 陈 璐2; 王丽洁1
(1.黑龙江中医药大学附属第一医院呼吸科,黑龙江 哈尔滨 150040; 2.黑龙江中医药大学研究生院,黑龙江 哈尔滨 150040)
Author(s):
LI Zhuying; CHEN Lu; WANG Lijie
(Department of Respiratory,the First Affiliated Hospital of Heilongjiang University of Chinese Medicine,Harbin 150040,China)
关键词:
麻黄-白果;  异病同治;  哮喘;  慢性阻塞性肺疾病;  药理机制
Keywords:
Ephedra and Ginkgo;  Treating different diseases with the same treatment;  Asthma;  Chronic obstructive pulmonary disease;  Pharmacology mechanism
分类号:
R 285
DOI:
DOI:10.3969/j.issn.1000-7369.2020.08.035
文献标志码:
A
摘要:
目的:采用网络药理学方法预测麻黄-白果药对治疗支气管哮喘(简称哮喘)和慢性阻塞性肺疾病(简称慢阻肺)的活性成分、靶点与信号通路,以探讨此药对“异病同治”的共同作用机制。方法:基于中药系统药理学数据库与分析平台获取麻黄-白果药对的活性化学成分及其对应靶点,通过Genecards数据库获取哮喘和慢阻肺相关靶点,将药对靶点与疾病靶点映射得到麻黄-白果药对作用于哮喘和慢阻肺的共同靶点。在Cytoscape软件中构建药对-活性成分-靶点-疾病网络,采用STRING在线数据库获取蛋白相互作用(PPI)数据。利用Bioconductor生物信息软件包对共同作用靶点进行KEGG通路富集分析。利用Auto Dock进行分子对接验证“异病同治”关键靶点和活性成分的相互作用。结果:通过筛选获得25个麻黄-白果药对的活性成分,108个麻黄-白果药对作用于哮喘和慢阻肺的共同靶点。富集分析结果表明麻黄-白果药对主要通过调节TNF信号通路、IL-17信号通路、HIF-1信号通路和Toll样受体信号通路等通路发挥对哮喘和慢阻肺的治疗作用。分子对接结果显示,“异病同治”关键靶点和活性成分之间具有较强的结合性。结论:麻黄-白果药对通过多成分、多靶点、多通路发挥了对哮喘和慢性阻塞性肺疾病“异病同治”的药效作用。
Abstract:
Objective:To predict the active components,targets and singal pathways of Ephedra and Ginkgo couplet medicine in the treatment of asthma and COPD by used the method of network pharmacology,so as to explore the common mechanism of “treating different diseases with the same treatment”.Methods:The effective chemical ingredients and corresponding targets of Ephedra and Ginkgo couplet medicine were obtained through TCMSP.Genecards was used to predict and screen the targets of asthma and COPD.The common targets of Ephedra and Ginkgo couplet medicine on asthma and COPD were obtained by mapping couplet medicine targets and disease targets.Couplet medicine-compound-target-disease network was constructed using Cytoscape software.Use STRING online database to obtain protein interaction(PPI)data.Bioconductor was used to analyze KEGG pathway enrichment of the targets.Use Auto Dock to carry out molecular docking to verify the interaction between active ingredients and key targets of “treating different diseases with the same treatment”.Results:25 chemical components of Ephedra and Ginkgo couplet medicine were obtained by database,108 potential targets of Ephedra and Ginkgo couplet medicine on asthma and COPD were obtained.The enrichment analysis results showed that Ephedra and Ginkgo couplet medicine mainly regulates TNF signaling pathway,IL-17 signaling pathway,HIF-1 signaling pathway,Toll-like receptor signaling pathway and other pathways to play a therapeutic effect on asthma and COPD.The results of molecular docking show that there is a strong binding between active ingredients and key targets of “treating different diseases with the same treatment”.Conclusion:Ephedra and Ginkgo couplet medicine exerts the effect of “treating different diseases with the same treatment” in asthma and COPD through multi-component,multi-target and multi-signal pathway.

参考文献/References:

[1] 杨昕宇,肖长芳,张凯熠,等.麻黄临床应用与药理作用研究进展[J].中华中医药学刊,2015,33(12):2874-2877.
[2] 刘志刚,柴程芝.基于药性结合药理的麻黄药证研究[J].中国中药杂志,2019,44(18):3883-3889.
[3] 夏梦雨,张 雪,王 云,等.白果的炮制方法、化学成分、药理活性及临床应用的研究进展[J].中国药房,2020,31(1):123-128.
[4] 赵珮妮,和法涛,宋 烨,等.白果的特异生物活性和药理作用研究进展[J].化工进展,2017,36(1):366-371.
[5] 徐森楠,庄 莉,翟园园,等.基于网络药理学研究二至丸防治骨质疏松症的物质基础与作用机制[J].中国药学杂志,2018,53(22):1913-1920.
[6] 马钦海,陈瑞晗,杨子峰.基于网络药理学和分子对接探讨六神胶囊治疗COVID-19的物质基础及作用机制[J].南京中医药大学学报,2020,36(6):907-914.
[7] 战海涛,范志强,陈新卫,等.血清IL-6、IL-10及TNF-α的水平变化在支气管哮喘患者中的临床意义[J].中国实验诊断学,2019,23(10):1741-1743.
[8] 孟凡飞,李 毅,孟凡娜,等.三指标联合检测对慢性阻塞性肺疾病急性加重期的预测价值[J].标记免疫分析与临床,2020,27(9):1468-1472.
[9] 史方海,陈忠仁.虎杖苷对慢性阻塞性肺疾病大鼠PI3K/AKT/mTOR通路以及气道炎症的影响[J].药物评价研究,2020,43(10):1983-1987.
[10] 姜碧杰,袁明洋,刘 扬,等.HMGB1信号通路联合AKT调控气道重塑作用[J].中国公共卫生,2020,36(4):654-656.
[11] 吴 刚.慢性阻塞性肺疾病患者血清基质金属蛋白酶、VEGF水平的变化及其临床意义[J].临床肺科杂志,2018,23(1):79-83.
[12] 王 玮,崔 婷.miR-20b通过调节MAPK/ERK途径对COPD动物模型气道炎症改善情况及作用机制研究[J].国际呼吸杂志,2020,40(23):1766-1770.
[13] 武明云,虞坚尔,薛 征,等.基于MAPK信号通路的中药治疗支气管哮喘的实验研究进展[J].上海中医药大学学报,2019,33(2):86-91.
[14] 杨晓敏,赵娜妹,刘 娟,等.健脾益肺化痰方通过抑制TNF-α信号通路改善COPD大鼠气道黏液高分泌的实验研究[J].天津中医药,2016,33(5):295-298.
[15] 赵倩楠,李文文,李 鑫,等.白介素-17在重症哮喘中作用的研究进展[J].中华临床医师杂志:电子版,2019,13(2):147-151.
[16] 孙 印,韦海燕.慢阻肺患者血清IL-17 TLR4水平与FEV1% predm MRC分级及CAT评分的相关性[J].河北医学,2020,26(10):1630-1633.
[17] 汪 迎.HIF-1、VEGF在慢性阻塞性肺疾病中的表达及临床意义[D].南昌:南昌大学,2019.
[18] 刘巧维.HIF-1α与Th17/Treg失衡对烟雾暴露哮喘大鼠气道炎症的影响及西罗莫司治疗作用的研究[D].北京:中国人民解放军军医进修学院,2013.
[19] 陆嘉玮,王 谦,赵祥安,等.Toll样受体与支气管哮喘关系的研究进展[J].山东医药,2017,57(12):104-107.
[20] 杨丽霞,贾钦尧,陈 艳,等.Toll样受体2、4/MyD88/NF-κB信号通路及相关分子在COPD发病机制中的作用及临床意义[J].西部医学,2020,32(12):1811-1815,1820.

相似文献/References:

[1]刘伊莎,李耀辉Δ,李 哲.从气机探讨麻黄连翘赤小豆汤证治病机和肺系疾病临床应用进展*[J].陕西中医,2020,(12):1846.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.044]
[2]王 兴,郭 珍,杨志宏.杨志宏教授运用清心宁神汤异病同治经验[J].陕西中医,2023,(6):773.[doi:DOI:10.3969/j.issn.1000-7369.2023.06.021]
　WANG Xing,GUO Zhen,YANG Zhihong.Professor Yang Zhihong used the experience of homotherapy for heteropathy with Qingxin Ningshen decoction[J].,2023,(8):773.[doi:DOI:10.3969/j.issn.1000-7369.2023.06.021]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助面上项目(82074365); 黑龙江省自然科学基金资助面上项目(H2017068); 黑龙江中医药大学科研基金资助面上项目(201824)
更新日期/Last Update: 2021-08-09